- Home
- SVII vs KPTI Comparison
SVII vs KPTI Comparison
Compare SVII & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- KPTI
- Stock Information
- Founded
- SVII 2021
- KPTI 2008
- Country
- SVII United States
- KPTI United States
- Employees
- SVII N/A
- KPTI N/A
- Industry
- SVII Blank Checks
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- SVII Finance
- KPTI Health Care
- Exchange
- SVII Nasdaq
- KPTI Nasdaq
- Market Cap
- SVII 111.1M
- KPTI 90.7M
- IPO Year
- SVII 2022
- KPTI 2013
- Fundamental
- Price
- SVII $11.28
- KPTI $0.69
- Analyst Decision
- SVII
- KPTI Strong Buy
- Analyst Count
- SVII 0
- KPTI 4
- Target Price
- SVII N/A
- KPTI $5.00
- AVG Volume (30 Days)
- SVII 7.2K
- KPTI 1.0M
- Earning Date
- SVII 01-01-0001
- KPTI 02-27-2025
- Dividend Yield
- SVII N/A
- KPTI N/A
- EPS Growth
- SVII 13.16
- KPTI N/A
- EPS
- SVII 0.36
- KPTI N/A
- Revenue
- SVII N/A
- KPTI $148,442,000.00
- Revenue This Year
- SVII N/A
- KPTI $5.47
- Revenue Next Year
- SVII N/A
- KPTI $6.33
- P/E Ratio
- SVII $31.25
- KPTI N/A
- Revenue Growth
- SVII N/A
- KPTI 1.77
- 52 Week Low
- SVII $10.87
- KPTI $0.58
- 52 Week High
- SVII $11.70
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- SVII 63.22
- KPTI 47.36
- Support Level
- SVII $11.20
- KPTI $0.61
- Resistance Level
- SVII $11.24
- KPTI $0.73
- Average True Range (ATR)
- SVII 0.00
- KPTI 0.07
- MACD
- SVII 0.00
- KPTI -0.00
- Stochastic Oscillator
- SVII 100.00
- KPTI 34.06
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.